FilingReader Intelligence
WuXi Biologics reports 16% revenue growth in H1
August 19, 2025 at 05:00 PM UTC•By FilingReader AI
WuXi Biologics reported 16.1% revenue growth to 9.95 billion yuan and 54.8% net profit rise to 2.76 billion yuan for the first half of 2025.
The company added 86 new integrated projects, including two late-stage projects, bringing its total integrated projects to 864.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
News Alerts
Get instant email alerts when WuXi Biologics (Cayman) Inc publishes news
Free account required • Unsubscribe anytime